Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Sep 25, 2020

Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting

Sep 08, 2020

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Aug 11, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

Aug 11, 2020

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

Aug 06, 2020

Fulcrum Therapeutics to Participate in Upcoming Investor Conferences

Aug 05, 2020

Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8:00 a.m. ET

Jul 21, 2020

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

Jun 24, 2020

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

Jun 10, 2020

Fulcrum Therapeutics Completes $68.5 Million Private Placement

Jun 10, 2020

Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 24

Investor Tools

Privacy Policy
EU Privacy Policy
Terms of Use

Twitter
LinkedIn
Instagram

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact